Benzinga | Mar 24, 2021 04:26PM EDT

Navidea Biopharmaceutical Q4 EPS $(0.11) Beats $(0.12) Estimate, Sales $219.25K Miss $600.00K Estimate

Navidea Biopharmaceutical (AMEX:NAVB) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 26.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $219.25 thousand which missed the analyst consensus estimate of $600.00 thousand by 63.46 percent. This is a 83.78 percent increase over sales of $119.30 thousand the same period last year.